Soluble ICAM-1 is modulated by hyperbaric oxygen treatment and correlates with disease severity and mortality in patients with necrotizing soft-tissue infection
Morten Hedetoft, Claus Moser, Peter Østrup Jensen, Julie Vinkel, Ole Hyldegaard
Abstract
treatment may be a promising immunomodulatory agent by increasing sICAM-1, thereby lowering risk of collateral damage, especially in the most critically ill patients. sICAM-1 is associated with disease severity in NSTI as emphasized by significant correlations with SAPS II. Low sICAM-1 levels are an independent risk factor of 90-day mortality and appeared to give a good level of diagnostic accuracy, suggesting that sICAM-1 can be used as a prognostic biomarker for NSTI.
Topics & Concepts
Interquartile rangeMedicineSeptic shockInternal medicineIntercellular Adhesion Molecule-1Endothelial activationPathophysiologyGastroenterologySepsisSystemic inflammatory response syndromeOdds ratioImmunologyInflammationStreptococcal Infections and TreatmentsAntimicrobial Resistance in StaphylococcusNeonatal and Maternal Infections